Illuminating the Druggable Genome Resource Dissemination and Outreach Center (IDG-RDOC)

照亮可药物基因组资源传播和外展中心 (IDG-RDOC)

• 批准号: 10063591
• 负责人: TUDOR I OPREA
• 金额: $ 73.14万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-12-01 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10063591
• 关键词: Adoption; Biocompatible Materials; Biological; Biological Assay; Biological Models; Biology; Biomedical Engineering; Chemicals; Collaborations; Collection; Communities; Community Outreach; Data; Data Science; Data Set; Development; Disease; Drug Targeting; Ecosystem; Education and Outreach; Experimental Models; Family; Flow Cytometry; Foundations; Funding; G-Protein-Coupled Receptors; Generations; Genome; Genomics; Guidelines; Human; Human Genome Project; Infrastructure; International; Investigation; Ion Channel; Laboratories; Medical; Molecular Bank; Molecular Structure; Morphologic artifacts; New Mexico; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Policies; Process; Production; Protein Kinase; Proteins; Proteome; Protocols documentation; Publications; Reagent; Reporting; Reproducibility; Research; Research Personnel; Research Project Grants; Resolution; Resource Sharing; Resources; Services; System; Technology; Teleconferences; Terminology; Time; Training; Training Programs; Training and Education; United States National Institutes of Health; Universities; Work; clinical development; data exchange; data resource; data sharing networks; data standards; data tools; drug discovery; experience; genome resource; interoperability; meetings; member; metadata standards; novel; novel therapeutics; open innovation; operation; outreach; outreach program; pre-clinical; programs; repository; screening; small molecule; success; technology development; tool; training opportunity; web based interface; working group

PROJECT SUMMARY As the Human Genome Project (HGP) approached its successful conclusion, NIH was in the process of formulating the Roadmap, which evolved into the Common Fund. At the leading edge of these initiatives was the Biomedical Engineering Research Partnership (BRP), which promoted technology development. For the BRP, Sklar led the development of high throughput flow cytometry, a screening technology which transitioned into the Molecular Libraries Program (MLP), a logical successor to the HGP, to develop small molecule probes for newly discovered genomic targets. For the Common Fund, Illuminating the Druggable Genome (IDG) became the next logical successor to prioritize genomic targets for further investigation. The technology advanced via the BRP by Sklar became a foundation for the collaboration with Oprea resulting in 10 years of participation in the MLP through both pilot and production phases, with Sklar leading both administrative and laboratory efforts and Oprea leading the data science efforts. Toward the end of the MLP, Oprea, Sklar, and Schürer, who had also been part of the MLP since the pilot phase, joined forces for the BARD initiative (2012- 14) and again in Phase I (2015-17) and this Phase II IDG proposal (2018-24). Despite steady progress in developing novel therapeutics and their enormous medical and societal benefits, current drugs target only a small fraction of the human proteome. Even drugs in clinical development and most preclinical drug discovery research ignore a significant portion of the druggable proteome. Through the development, broad dissemination, and use of community scientific resources, the IDG program is focused on advancing research to study human proteins for which publicly available information or active research is currently lacking, in order to catalyze the discovery of novel biology with a particular focus on understudied members of the protein kinase, ion channel, and non-olfactory GPCR families. Our highly-coordinated team from the University of New Mexico and the University of Miami will establish the IDG Resource Dissemination and Outreach Center (RDOC) to facilitate widespread access to consortium- generated data and resources as well as to serve the overall administration of the IDG Consortium and its relationships with external partners. The IDG-RDOC will work with all IDG Consortium investigators to collect and curate information regarding critical tools and reagents being developed by the IDG Consortium and disseminate them through the IDG Portal. Specifically we will: (i) coordinate and support the IDG consortium via a highly experienced administrative team; (ii) facilitate and coordinate external partnerships, outreach, and training related to IDG program activities; and (iii) develop and implement data standards, policies, operations, and tools to collect, curate, identify, and disseminate IDG-generated resources in accordance with (extended) NIH FAIR (Findable, Accessible, Attributable, Interoperable, Reusable, Reproducible) principles. 1"

项目摘要 随着人类基因组计划（HGP）接近成功，NIH正在进行 制定了路线图，该路线图发展成为共同基金。 生物医学工程研究伙伴关系（BRP），促进了技术发展。为 BRP，Sklar领导了高通量流式细胞术的开发，这是一种筛选技术， 进入分子库计划（MLP），HGP的逻辑继承者，开发小分子探针 新发现的基因组靶点为共同基金，照亮可药用基因组（IDG） 成为下一个合理的继任者，优先考虑基因组目标，以进行进一步的研究。技术 Sklar通过BRP推进的技术成为与Oprea合作的基础， 通过试点和生产阶段参与MLP，Sklar领导行政和 实验室的努力和Oprea领导的数据科学工作。在MLP结束时，Oprea，Sklar和 Schürer自试点阶段以来也是MLP的一部分，他加入了BARD倡议（2012- 14)第一阶段（2015-17年）和IDG第二阶段（2018-24年）也是如此。 尽管在开发新的治疗方法及其巨大的医疗和社会效益方面取得了稳步进展， 目前的药物仅靶向一小部分人类蛋白质组。即使是临床开发中的药物， 临床前药物发现研究忽略了可药用蛋白质组的重要部分。通过 开发、广泛传播和使用社区科学资源，IDG计划的重点是 推进研究人类蛋白质的研究，其中公开可用的信息或积极的研究是 目前缺乏，以促进新的生物学的发现，特别是对未充分研究的 蛋白激酶、离子通道和非嗅觉GPCR家族的成员。 我们来自新墨西哥州大学和迈阿密大学的高度协调的团队将建立 IDG资源传播和外展中心（RDOC），以促进广泛获得联盟- 产生的数据和资源，以及服务于IDG联盟的整体管理及其 与外部合作伙伴的关系。IDG-RDOC将与所有IDG联盟调查员合作， 并策划有关IDG联盟正在开发的关键工具和试剂的信息， 通过IDG门户网站进行传播。具体而言，我们将：（i）协调和支持IDG财团 通过一个经验丰富的行政团队;（二）促进和协调外部伙伴关系，外联， 与IDG计划活动相关的培训;以及（iii）制定和实施数据标准、政策、运营， 收集、管理、识别和传播IDG生成的资源的工具（扩展） NIH FAIR（Findable，Interoperable，Releasable，Attributable，Interoperable，Reusable，Reproducible）原则 1”